Combining Lumipulse pTau217 and Aβ42 as confirmatory tests for Aβ pathology prior to DMT

Abstract

Background: With the increasing number of countries approving disease‐modifying therapies (DMTs) for patients with either Mild Cognitive Impairment (MCI) or mild Alzheimer's disease (AD), it is vitally important to streamline treatment assessment processes.